File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1002/hep.1840090119
- Scopus: eid_2-s2.0-0024541162
- PMID: 2461890
- WOS: WOS:A1989R509900018
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: α-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: Role in the early detection of hepatocellular carcinoma
Title | α-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: Role in the early detection of hepatocellular carcinoma |
---|---|
Authors | |
Issue Date | 1989 |
Publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/ |
Citation | Hepatology, 1989, v. 9 n. 1, p. 110-115 How to Cite? |
Abstract | Two hundred ninety patients (203 men, 87 women), age 7 to 74 years (mean: 39.1 years), with chronic hepatitis B virus infection, were prospectively followed for a period of 1 to 4 years to determine the value of α-fetoprotein monitoring in the early detection of hepatocellular carcinoma. At presentation, 66% of the patients were asymptomatic, 19% had chronic hepatitis and 15% had established cirrhosis. Forty-four (15%) patients had elevated α-fetoprotein levels on one or more occasions during the study period. Twenty patients with normal α-fetoprotein levels at presentation developed elevated α-fetoprotein levels during the course of follow-up, whereas 24 patients had elevated α-fetoprotein levels at presentation. Six (14%) of these 44 patients (five men and one woman), age 23 to 66 years, had persistent or progressive increase in α-fetoprotein levels and were confirmed to have hepatocellular carcinoma. In four patients, the α-fetoprotein levels were below 500 ng per ml at the time of tumor localization. Only three patients had resectable tumors. All six patients would have been missed if α-fetoprotein screening was restricted to men above the age of 40 with cirrhosis and anti-HBe. Of the remaining 38 patients, elevation in α-fetoprotein levels in 18 patients was associated with exacerbations of the underlying liver disease and/or significant changes in level of hepatitis B virus replication, but in 20 patients, no apparent cause could be identified. The elevation in AFP levels exceeded 200 ng per ml in 26% and persisted beyond 6 months in 15% of these patients. We observed that elevation in α-fetoprotein levels occurred quite frequently in patients with chronic hepatitis B virus infection. The differentiation between benign and malignant causes of α-fetoprotein elevation was at times difficult. Thus, α-fetoprotein monitoring alone is not a satisfactory tool in the early diagnosis of hepatocellular carcinoma. |
Persistent Identifier | http://hdl.handle.net/10722/161795 |
ISSN | 2023 Impact Factor: 12.9 2023 SCImago Journal Rankings: 5.011 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lok, ASF | en_US |
dc.contributor.author | Lai, CL | en_US |
dc.date.accessioned | 2012-09-05T05:15:05Z | - |
dc.date.available | 2012-09-05T05:15:05Z | - |
dc.date.issued | 1989 | en_US |
dc.identifier.citation | Hepatology, 1989, v. 9 n. 1, p. 110-115 | en_US |
dc.identifier.issn | 0270-9139 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/161795 | - |
dc.description.abstract | Two hundred ninety patients (203 men, 87 women), age 7 to 74 years (mean: 39.1 years), with chronic hepatitis B virus infection, were prospectively followed for a period of 1 to 4 years to determine the value of α-fetoprotein monitoring in the early detection of hepatocellular carcinoma. At presentation, 66% of the patients were asymptomatic, 19% had chronic hepatitis and 15% had established cirrhosis. Forty-four (15%) patients had elevated α-fetoprotein levels on one or more occasions during the study period. Twenty patients with normal α-fetoprotein levels at presentation developed elevated α-fetoprotein levels during the course of follow-up, whereas 24 patients had elevated α-fetoprotein levels at presentation. Six (14%) of these 44 patients (five men and one woman), age 23 to 66 years, had persistent or progressive increase in α-fetoprotein levels and were confirmed to have hepatocellular carcinoma. In four patients, the α-fetoprotein levels were below 500 ng per ml at the time of tumor localization. Only three patients had resectable tumors. All six patients would have been missed if α-fetoprotein screening was restricted to men above the age of 40 with cirrhosis and anti-HBe. Of the remaining 38 patients, elevation in α-fetoprotein levels in 18 patients was associated with exacerbations of the underlying liver disease and/or significant changes in level of hepatitis B virus replication, but in 20 patients, no apparent cause could be identified. The elevation in AFP levels exceeded 200 ng per ml in 26% and persisted beyond 6 months in 15% of these patients. We observed that elevation in α-fetoprotein levels occurred quite frequently in patients with chronic hepatitis B virus infection. The differentiation between benign and malignant causes of α-fetoprotein elevation was at times difficult. Thus, α-fetoprotein monitoring alone is not a satisfactory tool in the early diagnosis of hepatocellular carcinoma. | en_US |
dc.language | eng | en_US |
dc.publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/ | en_US |
dc.relation.ispartof | Hepatology | en_US |
dc.subject.mesh | Age Factors | en_US |
dc.subject.mesh | Carcinoma, Hepatocellular - Diagnosis | en_US |
dc.subject.mesh | Chronic Disease | en_US |
dc.subject.mesh | Hepatitis B - Blood | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Liver Neoplasms - Diagnosis | en_US |
dc.subject.mesh | Prospective Studies | en_US |
dc.subject.mesh | Taiwan | en_US |
dc.subject.mesh | Time Factors | en_US |
dc.subject.mesh | Alpha-Fetoproteins - Analysis | en_US |
dc.title | α-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: Role in the early detection of hepatocellular carcinoma | en_US |
dc.type | Article | en_US |
dc.identifier.email | Lai, CL:hrmelcl@hku.hk | en_US |
dc.identifier.authority | Lai, CL=rp00314 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1002/hep.1840090119 | - |
dc.identifier.pmid | 2461890 | - |
dc.identifier.scopus | eid_2-s2.0-0024541162 | en_US |
dc.identifier.volume | 9 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.spage | 110 | en_US |
dc.identifier.epage | 115 | en_US |
dc.identifier.isi | WOS:A1989R509900018 | - |
dc.publisher.place | United States | en_US |
dc.identifier.scopusauthorid | Lok, ASF=35379868500 | en_US |
dc.identifier.scopusauthorid | Lai, CL=7403086396 | en_US |
dc.identifier.issnl | 0270-9139 | - |